These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 16827966)
21. RNA interference inhibits hepatitis B virus gene expression and replication in HepG2-N10 cells. Ren JL; Pan JS; Cheng T; Dong J; Lu YP; Huang SJ; Shi HX; Wang L; Lian YM Chin J Dig Dis; 2006; 7(4):230-6. PubMed ID: 17054586 [TBL] [Abstract][Full Text] [Related]
22. Conditional RNAi: towards a silent gene therapy. Lee SK; Kumar P Adv Drug Deliv Rev; 2009 Jul; 61(7-8):650-64. PubMed ID: 19394374 [TBL] [Abstract][Full Text] [Related]
24. A retrovirus-based system to stably silence hepatitis B virus genes by RNA interference. Jia F; Zhang YZ; Liu CM Biotechnol Lett; 2006 Oct; 28(20):1679-85. PubMed ID: 16900331 [TBL] [Abstract][Full Text] [Related]
25. RNA interference: implications for cancer treatment. Masiero M; Nardo G; Indraccolo S; Favaro E Mol Aspects Med; 2007 Feb; 28(1):143-66. PubMed ID: 17307250 [TBL] [Abstract][Full Text] [Related]
26. Nonviral vector-mediated RNA interference: its gene silencing characteristics and important factors to achieve RNAi-based gene therapy. Takahashi Y; Nishikawa M; Takakura Y Adv Drug Deliv Rev; 2009 Jul; 61(9):760-6. PubMed ID: 19386274 [TBL] [Abstract][Full Text] [Related]
27. The potential of oligonucleotides for therapeutic applications. Fichou Y; Férec C Trends Biotechnol; 2006 Dec; 24(12):563-70. PubMed ID: 17045686 [TBL] [Abstract][Full Text] [Related]
31. Technology insight: therapeutic RNA interference--how far from the neurology clinic? Gonzalez-Alegre P; Paulson HL Nat Clin Pract Neurol; 2007 Jul; 3(7):394-404. PubMed ID: 17611488 [TBL] [Abstract][Full Text] [Related]
32. siRNA vs. shRNA: similarities and differences. Rao DD; Vorhies JS; Senzer N; Nemunaitis J Adv Drug Deliv Rev; 2009 Jul; 61(9):746-59. PubMed ID: 19389436 [TBL] [Abstract][Full Text] [Related]
33. Commercial potential of RNAi. Jain KK Mol Biosyst; 2006 Nov; 2(11):523-6. PubMed ID: 17216033 [TBL] [Abstract][Full Text] [Related]
34. RNAi-mediated knockdown of target genes: a promising strategy for pancreatic cancer research. Chang H Cancer Gene Ther; 2007 Aug; 14(8):677-85. PubMed ID: 17541422 [TBL] [Abstract][Full Text] [Related]
35. Potential role of RNAi in the treatment of HCV infection. Volarevic M; Smolic R; Wu CH; Wu GY Expert Rev Anti Infect Ther; 2007 Oct; 5(5):823-31. PubMed ID: 17914916 [TBL] [Abstract][Full Text] [Related]
37. RNAi-mediated inhibition of the glucosylceramide synthase (GCS) gene: A preliminary study towards a therapeutic strategy for Gaucher disease and other glycosphingolipid storage diseases. Diaz-Font A; Chabás A; Grinberg D; Vilageliu L Blood Cells Mol Dis; 2006; 37(3):197-203. PubMed ID: 16959503 [TBL] [Abstract][Full Text] [Related]
38. Strategies for short hairpin RNA delivery in cancer gene therapy. Wang SL; Yao HH; Qin ZH Expert Opin Biol Ther; 2009 Nov; 9(11):1357-68. PubMed ID: 19761417 [TBL] [Abstract][Full Text] [Related]
39. RNA interference for studying the molecular basis of neuropsychiatric disorders. Hoyer D Curr Opin Drug Discov Devel; 2007 Mar; 10(2):122-9. PubMed ID: 17436547 [TBL] [Abstract][Full Text] [Related]
40. Hepatitis B virus is inhibited by RNA interference in cell culture and in mice. Ying RS; Zhu C; Fan XG; Li N; Tian XF; Liu HB; Zhang BX Antiviral Res; 2007 Jan; 73(1):24-30. PubMed ID: 16844238 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]